Bridge Realization Estimate
ML model predicts what fraction of the bridge is achievable (accuracy: 60%, n=5,839)
Expected realization: 68% of modeled bridge. Risk-adjusted uplift: $7.9M (vs $11.6M modeled).
EBITDA Bridge — 7 RCM Levers
Each bar shows the annual EBITDA impact at full run-rate. Revenue levers increase top-line; cost levers reduce operating expense; cash acceleration releases working capital. Calibrated to published research bands (Denial 12%→5% = $8-15M on $400M NPR).
Lever Detail
Each value shows its data source. SELLER = seller data room, DEFAULT = model default, BENCHMARK = P75 peer benchmark.
| Lever | Current | Target | Revenue | Cost | EBITDA | WC | Ramp |
|---|---|---|---|---|---|---|---|
| Cost to Collect | 4.5% DEFAULT | 2.5% BENCHMARK | $0 | $4.4M | $4.4M | $0 | 12mo |
| Denial Rate Reduction | 12.0% DEFAULT | 6.5% BENCHMARK | $4.3M | $122K | $4.4M | $0 | 12mo |
| A/R Days Reduction | 52.00 DEFAULT | 38.00 BENCHMARK | $678K | $2.0M | $2.7M | $8.5M | 9mo |
| Clean Claim Rate | 88.0% DEFAULT | 96.0% BENCHMARK | $0 | $141K | $141K | $0 | 6mo |
| Net Collection Rate | 93.5% DEFAULT | 30.5% BENCHMARK | $0 | $0 | $0 | $0 | 18mo |
| CDI / Case Mix Index | 135.0% DEFAULT | 142.0% BENCHMARK | $0 | $0 | $0 | $0 | 18mo |
Implementation Timing Curve
Linear ramp to full run-rate per lever. Month 0 = close date. Partners should expect 60-70% of total uplift realized by month 12.
| Lever | M0 | M3 | M6 | M9 | M12 | M18 | M24 | M36 |
|---|---|---|---|---|---|---|---|---|
| Cost to Collect | $0 | $1.1M | $2.2M | $3.3M | $4.4M | $4.4M | $4.4M | $4.4M |
| Denial Rate Reduction | $0 | $1.1M | $2.2M | $3.3M | $4.4M | $4.4M | $4.4M | $4.4M |
| A/R Days Reduction | $0 | $897K | $1.8M | $2.7M | $2.7M | $2.7M | $2.7M | $2.7M |
| Clean Claim Rate | $0 | $71K | $141K | $141K | $141K | $141K | $141K | $141K |
| Cumulative | $0 | $3.2M | $6.3M | $9.4M | $11.6M | $11.6M | $11.6M | $11.6M |
Returns Sensitivity (IRR / MOIC)
5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Green = exceeds 20% IRR hurdle. Amber = 15-20%. Red = below hurdle or loss. RCM uplift of $11.6M is added at exit.
| Entry \ Exit | 9.0x | 10.0x | 11.0x | 11.5x | 12.0x |
|---|---|---|---|---|---|
| 8.0x | 61% / 10.8x | 65% / 12.3x | 69% / 13.9x | 71% / 14.7x | 73% / 15.4x |
| 9.0x | 56% / 9.2x | 60% / 10.6x | 64% / 12.0x | 66% / 12.7x | 68% / 13.4x |
| 10.0x | 51% / 8.0x | 56% / 9.2x | 60% / 10.5x | 62% / 11.1x | 64% / 11.7x |
| 11.0x | 47% / 7.0x | 52% / 8.1x | 56% / 9.2x | 58% / 9.8x | 60% / 10.3x |
| 12.0x | 44% / 6.1x | 48% / 7.1x | 52% / 8.2x | 54% / 8.7x | 56% / 9.2x |
Covenant Headroom (at 10x Entry, 6.5x Max Leverage)
Pro forma EBITDA can decline 26% before the 6.5x covenant trips. RCM uplift reduces leverage from 8.5x to 4.8x, adding 3.6 turns of cushion.
5-Year Value Creation Waterfall
EBITDA trajectory: 3% organic growth + RCM uplift ramp (full run-rate at month 18).
| Base EBITDA | RCM Uplift | Total | Margin | |
|---|---|---|---|---|
| Entry | $15.3M | — | $15.3M | 6.9% |
| Year 1 | $15.8M | +$7.8M | $23.6M | 10.7% |
| Year 2 | $16.3M | +$11.6M | $27.9M | 12.6% |
| Year 3 | $16.8M | +$11.6M | $28.4M | 12.8% |
| Year 4 | $17.3M | +$11.6M | $28.9M | 13.1% |
| Year 5 | $17.8M | +$11.6M | $29.4M | 13.3% |
Achievement Sensitivity
What if we only achieve a fraction of each lever? 50% = conservative, 75% = base management case, 100% = plan, 120% = stretch.
| Lever | 50% | 75% | 100% | 120% |
|---|---|---|---|---|
| Cost to Collect | $2.2M | $3.3M | $4.4M | $5.3M |
| Denial Rate Reductio | $2.2M | $3.3M | $4.4M | $5.3M |
| A/R Days Reduction | $1.3M | $2.0M | $2.7M | $3.2M |
| Clean Claim Rate | $71K | $106K | $141K | $170K |
| Total | $5.8M | $8.7M | $11.6M | $14.0M |
Peer Context — Where This Hospital Sits
Key metrics vs 30 size-matched peers. Low percentile on margin/efficiency metrics = more room for improvement = larger bridge opportunity.
| Metric | Hospital | P25 | P50 | P75 | Percentile |
|---|---|---|---|---|---|
| Op Margin | 6.9% | -15.7% | -4.7% | 1.5% | P83 |
| Net-to-Gross | 22.6% | 10.3% | 21.8% | 30.5% | P52 |
| Occupancy | 53.7% | 29.1% | 39.7% | 54.8% | P67 |
| Rev/Bed | $1.4M | $469K | $689K | $1.1M | P93 |
| Exp/Bed | $1.3M | $410K | $719K | $1.1M | P80 |
Bridge Methodology
Coefficients calibrated to published research bands: denial 12%→5% = $8-15M on $400M NPR. Current metrics estimated from HCRIS public data and ML predictions. Target metrics set at P75 peer benchmarks with 60% gap closure assumption. Revenue levers use NPR × delta × avoidable share. Cost levers use claims volume × cost per reworked claim. Working capital from AR reduction is one-time cash (not included in recurring EBITDA). Returns assume 5.5x leverage, 3% organic growth, 10%/yr debt paydown.